Literature DB >> 12931223

Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients.

P Bernasconi1, P M Cavigliano, M Boni, S Calatroni, C Klersy, I Giardini, B Rocca, N Crosetto, M Caresana, M Lazzarino, C Bernasconi.   

Abstract

Conventional cytogenetics (CC) at clinical diagnosis shows a normal karyotype in 40-60% of de novo myelodysplastic syndromes (MDSs). Fluorescence in situ hybridization (FISH) might detect occult aberrations in these patients. Therefore, we have used FISH to check 57 MDS patients who were karyo-typically normal on CC. At clinical diagnosis, FISH revealed a clonal abnormality in 18-28% interphase cells from nine patients, five of whom also presented the same defect on metaphase FISH. In five out of nine patients, the occult defect effected a change in the international prognostic scoring system (IPSS). An abnormal FISH pattern was significantly correlated with marrow blast cell percentage (P<10(-3)) and IPSS (P<10(-3)). Patients with an occult abnormality showed an overall survival and event-free survival significantly inferior in comparison to those of patients with normal FISH (P<10(-3), P<10(-3)). Death and AML progression were 15- and eight-fold more frequent in FISH abnormal patients. In conclusion, occult defects (1) are revealed in about 15% of CC normal MDS patients, (2) are overlooked by CC either because of the poor quality of metaphases or their submicroscopic nature, (3) are clinically relevant as they may cause a change in the IPSS category and may identify a fraction of CC normal patients with an unfavorable clinical outcome.

Entities:  

Mesh:

Year:  2003        PMID: 12931223     DOI: 10.1038/sj.leu.2403108

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  11 in total

1.  Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide.

Authors:  Gudrun Göhring; Aristoteles Giagounidis; Guntram Büsche; Winfried Hofmann; Hans Heinrich Kreipe; Pierre Fenaux; Eva Hellström-Lindberg; Brigitte Schlegelberger
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

2.  Clinical utility of FISH analysis in addition to G-banded karyotype in hematologic malignancies and proposal of a practical approach.

Authors:  Won Kyung Kwon; Jin Young Lee; Yeung Chul Mun; Chu Myong Seong; Wha Soon Chung; Jungwon Huh
Journal:  Korean J Hematol       Date:  2010-09-30

3.  Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide.

Authors:  Sara A Monaghan; Lijun Dai; Markus Y Mapara; Daniel P Normolle; Susanne M Gollin; Suzanne Lentzsch
Journal:  Leuk Lymphoma       Date:  2013-01-28

4.  Myelodysplastic syndrome in elderly patients: correlation of CBC with cytogenetic and FISH analysis.

Authors:  K-E T Codispoti; L Depalma
Journal:  Int J Lab Hematol       Date:  2009-12-23       Impact factor: 2.877

5.  Evaluation of the utility of peripheral blood vs bone marrow in karyotype and fluorescence in situ hybridization for myelodysplastic syndrome diagnosis.

Authors:  Zhaleh Asadi Fakhr; Valiollah Mehrzad; Amin Izaditabar; Mansoor Salehi
Journal:  J Clin Lab Anal       Date:  2018-06-11       Impact factor: 2.352

Review 6.  The evaluation of the outcome in myelodysplastic patients by using non-cytogenetic prognostic scores.

Authors:  O Căzăceanu; Am Vlădăreanu; H Bumbea; M Begu; M Onisai; C Enache
Journal:  J Med Life       Date:  2014-09-25

Review 7.  Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease.

Authors:  Valeria Visconte; Ramon V Tiu; Heesun J Rogers
Journal:  Blood Res       Date:  2014-12-23

8.  Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.

Authors:  Peter Valent; Attilio Orazi; David P Steensma; Benjamin L Ebert; Detlef Haase; Luca Malcovati; Arjan A van de Loosdrecht; Torsten Haferlach; Theresia M Westers; Denise A Wells; Aristoteles Giagounidis; Michael Loken; Alberto Orfao; Michael Lübbert; Arnold Ganser; Wolf-Karsten Hofmann; Kiyoyuki Ogata; Julie Schanz; Marie C Béné; Gregor Hoermann; Wolfgang R Sperr; Karl Sotlar; Peter Bettelheim; Reinhard Stauder; Michael Pfeilstöcker; Hans-Peter Horny; Ulrich Germing; Peter Greenberg; John M Bennett
Journal:  Oncotarget       Date:  2017-07-05

9.  Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup.

Authors:  Elena Ciabatti; Angelo Valetto; Veronica Bertini; Maria Immacolata Ferreri; Alice Guazzelli; Susanna Grassi; Francesca Guerrini; Iacopo Petrini; Maria Rita Metelli; Maria Adelaide Caligo; Simona Rossi; Sara Galimberti
Journal:  Oncotarget       Date:  2017-03-25

10.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Authors:  Luca Malcovati; Eva Hellström-Lindberg; David Bowen; Lionel Adès; Jaroslav Cermak; Consuelo Del Cañizo; Matteo G Della Porta; Pierre Fenaux; Norbert Gattermann; Ulrich Germing; Joop H Jansen; Moshe Mittelman; Ghulam Mufti; Uwe Platzbecker; Guillermo F Sanz; Dominik Selleslag; Mette Skov-Holm; Reinhard Stauder; Argiris Symeonidis; Arjan A van de Loosdrecht; Theo de Witte; Mario Cazzola
Journal:  Blood       Date:  2013-08-26       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.